[Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino]

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Context:

• Duchenne muscular dystrophy (DMD) results from dystrophin deficiency, impacting muscle function.
• Antisense oligonucleotides (ASOs) offer a therapeutic strategy by enabling exon skipping to restore the dystrophin reading frame.
• Previous studies demonstrated successful dystrophin restoration in canine models using Morpholino ASOs.

Purpose:

• To optimize therapeutic antisense Morpholinos for frequent Duchenne muscular dystrophy (DMD) gene mutations.
• To design and test antisense Morpholinos targeting exon 51 in mdx52 mice, which have a deletion in exon 52.
• To evaluate both localized and systemic delivery of these ASOs in a mouse model.

Summary:

• Antisense Morpholinos targeting exon 51 of the mouse Duchenne muscular dystrophy (DMD) gene were designed and administered to mdx52 mice.
• Both localized intramuscular injections and systemic delivery were employed to assess exon skipping efficacy.
• The study aimed to verify the effectiveness and potential side effects of exon-skipping ASOs in this DMD mouse model.

Impact:

• This research validates the use of antisense Morpholinos for exon skipping in Duchenne muscular dystrophy (DMD) mouse models.
• Findings support the potential of ASO-based therapies for treating various DMD mutations.
• The study underscores the importance of preclinical testing in animal models before human clinical trials for Duchenne muscular dystrophy (DMD).